Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen, David R. Macdonald, David A. Reardon et al. · Journal of Clinical Oncology · 2010 · 3.8K citations · Full text

Medicine, Neurology, Oncology +15

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

Henry S. Friedman, Michael D. Prados, Patrick Y. Wen et al. · Journal of Clinical Oncology · 2009 · 2.4K citations

Medicine, Oncology, Pharmacology +17

Response criteria for phase II studies of supratentorial malignant glioma.

David R. Macdonald, T L Cascino, S. Clifford Schold et al. · Journal of Clinical Oncology · 1990 · 2.4K citations

Medicine, Oncology, Radiology +17

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

Tracy T. Batchelor, A. Gregory Sorensen, Emmanuelle di Tomaso et al. · Cancer Cell · 2007 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

Kathleen R. Lamborn, W.K. Alfred Yung, Susan M. Chang et al. · Neuro-Oncology · 2008 · 422 citations · Full text

Medicine, Neurology, Oncology +14